Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that reduces neuroinflammation and peripheral pain, showing efficacy in chronic pain conditions such as diabetic neuropathy, fibromyalgia, and osteoarthritis. It is well-tolerated with no known drug interactions.

painanti-inflammatoryneuroprotectionmoodsleep

Evidence last reviewed: 20 Apr 2026

Buy this ingredient ← Back

Supplement note

Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Biomarkers studied

Outcomes directly measured across the evidence records below

Inflammation

TNF-αIL-6

Evidence

4 records

Chronic pain reduction

Adults with chronic pain • Meta-analysis

PUBMEDHigh

PEA was associated with significantly greater pain reduction compared to inactive control conditions.

Dose: 600 mg

Citation: Gabrielsson et al. (2016). Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Journal of the American Chemical Society.

Proinflammatory marker reduction

Unvaccinated adults with COVID-19 • RCT

PUBMEDModerate

PEA reduced proinflammatory markers in adults recently diagnosed with COVID-19.

Dose: 600 mg

Citation: Fessler et al. (2022). Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial. Annual Review of Pharmacology and Toxicology.

Pain reduction in metabolic syndrome

Metabolic syndrome patients • RCT

PUBMEDLow

Preliminary results suggest PEA may aid in pain management for metabolic syndrome patients.

Dose: 600 mgForm: Co-micronized with Rutin

Citation: Cornali et al. (2025). The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results. Journal of Clinical Pharmacology.

Study focused on metabolic syndrome.

Acute menstrual pain reduction

Adults with menstrual pain • RCT

PUBMEDModerate

PEA significantly reduced acute menstrual pain scores compared to placebo.

Dose: 300 mgDuration: Single doseTiming: At pain onset

Study focused on menstrual pain relief.

Forms

Micronized

Enhanced absorption and bioavailability.

Co-micronized with Rutin

Combined with rutin for synergistic effects.

Levagen+

A branded form with improved solubility.

Stacks containing Palmitoylethanolamide (PEA)

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.